NASDAQ$PCVX
Vaxcyte Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Vaxcyte reported financial results for the second quarter ended June 30, 2023 and provided a business update.
Vaxcyte reported a net loss of $68.3 million for the second quarter of 2023. The company's cash, cash equivalents, and investments totaled $1,440.8 million as of June 30, 2023, including $545.3 million in net proceeds from an April public offering. Vaxcyte is advancing its PCV programs and anticipates key milestones, including regulatory interactions for VAX-24 and IND clearance for VAX-31.
- Completed VAX-24 Adult Phase 2 Program with Announcement of Positive Data in Adults 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies.
- Advanced to Second and Final Stage of Phase 2 Study Evaluating VAX-24 for the Prevention of IPD in Infants and Dosed First New Participants.
- Completed Successful $575 Million Follow-On Financing.
- Published New VAX-GI Preclinical Data and Received NIH Grants.
Headline financials
Revenue & EPS history
Vaxcyte · Revenue · Quarterly
$0
Forward guidance
Vaxcyte is advancing the clinical development of its PCV programs with several anticipated key upcoming milestones.
Tailwinds
- Several regulatory interactions to finalize the Company’s Phase 3 clinical program and Biologics License Application submission requirements including:
- An End-of-Phase 2 meeting with the FDA regarding the adult Phase 3 clinical program expected in the fourth quarter of 2023.
- Discussions afforded by the Breakthrough Therapy designation granted by the FDA, including meetings regarding the Company’s CMC strategy to occur through the first quarter of 2024.
- Topline safety, tolerability and immunogenicity data from the Phase 3 pivotal non-inferiority study in adults in 2025.
- Clearance of the adult IND application by the FDA in the fourth quarter of 2023 following submission.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+0.6%
Avg return
Earnings day
+0.8%
Avg return
5 days after
-0.2%
Avg return
30 days after
50%
11 / 22 earnings
Positive
+23.8%
Q2 2020
Best reaction
-21.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.7% | +1.0% | -13.3% | |
| Q3 2025 | -2.5% | +3.8% | +12.4% | |
| Q2 2025 | -9.1% | -9.1% | +0.1% | |
| Q1 2025 | +8.3% | +3.6% | +27.6% | |
| Q4 2024 | -0.9% | -9.1% | -12.5% | |
| Q3 2024 | -2.3% | +0.2% | -15.4% | |
| Q1 2024 | -2.9% | -2.7% | +5.1% | |
| Q4 2023 | -4.9% | -9.2% | -13.5% | |
| Q3 2023 | -1.0% | -5.1% | +10.8% | |
| Q2 2023 | -2.5% | -2.0% | +3.4% | |
| Q1 2023 | +3.7% | -3.7% | -0.3% | |
| Q4 2022 | -1.8% | +2.0% | -11.6% | |
| Q3 2022 | +4.2% | +3.3% | +0.6% | |
| Q2 2022 | +0.4% | +1.7% | +6.1% | |
| Q1 2022 | -11.4% | -3.0% | -14.8% | |
| Q4 2021 | +5.5% | +1.5% | +6.5% | |
| Q3 2021 | +3.4% | +4.7% | -12.7% | |
| Q2 2021 | +5.1% | +3.6% | +3.1% | |
| Q1 2021 | +13.5% | +17.0% | +40.5% | |
| Q4 2020 | -21.5% | -11.9% | -17.3% | |
| Q3 2020 | +3.9% | -0.2% | -15.3% | |
| Q2 2020 | +23.8% | +31.0% | +5.5% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro